Vaxcyte, Inc. (PCVX) financial statements (2022 and earlier)

Company profile

Business Address 825 INDUSTRIAL ROAD, STE. 300
SAN CARLOS, CA 94070
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments245,970386,200
Cash and cash equivalents68,985386,200
Short-term investments176,985 
Other undisclosed current assets10,3782,804
Total current assets:256,348389,004
Noncurrent Assets
Operating lease, right-of-use asset27,958 
Property, plant and equipment7,9543,272
Long-term investments and receivables27,117 
Long-term investments27,117 
Restricted cash and investments871 
Other noncurrent assets4,089550
Total noncurrent assets:67,9893,822
TOTAL ASSETS:324,337392,826
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities19,00033,835
Accounts payable6,75829,785
Accrued liabilities8,7873,766
Employee-related liabilities3,455284
Deferred rent credit 14
Due to related parties 677
Other undisclosed current liabilities9,71612,335
Total current liabilities:28,71646,861
Noncurrent Liabilities
Long-term debt and lease obligation11,507 
Operating lease, liability11,507 
Liabilities, other than long-term debt96122
Deferred rent credit 10
Other liabilities96112
Total noncurrent liabilities:11,603122
Total liabilities:40,31946,983
Stockholders' equity
Stockholders' equity attributable to parent284,018345,843
Common stock5654
Additional paid in capital582,844544,353
Accumulated other comprehensive loss(241) 
Accumulated deficit(298,641)(198,564)
Total stockholders' equity:284,018345,843
TOTAL LIABILITIES AND EQUITY:324,337392,826

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
Operating expenses(103,670)(89,581)
Operating loss:(103,670)(89,581)
Nonoperating income (expense)5,606(1,743)
Foreign currency transaction gain (loss), before tax1,669(2,351)
Other nonoperating income3,593364
Interest and debt expense(7)(7)
Loss before gain (loss) on sale of properties:(98,071)(91,331)
Other undisclosed net income (loss)(2,006)2,114
Net loss available to common stockholders, diluted:(100,077)(89,217)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
Net loss:(100,077)(89,217)
Comprehensive loss:(100,077)(89,217)
Other undisclosed comprehensive loss, net of tax, attributable to parent(241) 
Comprehensive loss, net of tax, attributable to parent:(100,318)(89,217)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: